VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments
Open Access
- 19 November 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6970
Abstract
VEXAS syndrome is a recently identified autoinflammatory disorder resulting from somatic mutations in the UBA1 gene, leading to a complex spectrum of severe inflammatory and hematologic manifestations. The absence of established treatment guidelines and the variability in clinical presentation make its management particularly challenging. Current therapeutic approaches are often based on limited evidence, and their effectiveness remains inconsistent. This review seeks to consolidate the existing knowledge on therapeutic strategies for VEXAS syndrome, offering a critical evaluation of their efficacy and addressing the gaps in the current literature. As the clinical recognition of VEXAS grows, there is an urgent need to explore more targeted, effective treatments that can address both the inflammatory and hematologic aspects of the disease. By providing a comprehensive analysis of the current therapeutic landscape, this review aims to guide clinicians and researchers toward developing more effective, long-term management strategies for this life-threatening condition.Keywords
This publication has 68 references indexed in Scilit:
- VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapyRheumatology, 2021
- Novel somatic mutations in UBA1 as a cause of VEXAS syndromeBlood, 2021
- Therapeutic options in VEXAS syndrome: insights from a retrospective seriesBlood, 2021
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory DiseaseNew England Journal of Medicine, 2020
- Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialThe Lancet, 2019
- Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reactionEuropean Annals of Allergy and Clinical Immunology, 2017
- NF-κB Pathway in Autoinflammatory Diseases: Dysregulation of Protein Modifications by Ubiquitin Defines a New Category of Autoinflammatory DiseasesFrontiers in Immunology, 2017
- Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemiaLeukemia Research, 2016
- Perilous journey: a tour of the ubiquitin–proteasome systemTrends in Cell Biology, 2014
- AzacitidineDrugs, 2009